There’s already a long list of fascinating reads about the professional and personal life of Clay Siegall, the CEO of the ever renowned Seattle Genetics. There’s not even a shortage of the factual data, feature articles about him online. However, the most accurate of them would have to be the ones that are able to offer the words that Siegall used themselves. And one of them would easily be the feature article about him that involves his interview with Inspirery.com.
The interview highlights some of the charismatic attributes, clear-eyed ideas and also clear-cut technological solutions and remedies that Siegall is initiating today. It is in the interview that people can read about how Siegall uses his B.S. in Zoology degree at The University of Maryland to improve the society. It is there that people can trace the growth of Siegall from his genetics study from George Washington University to his moves to grow Seattle Genetics.
The commanding way that the interview was done also presents some interesting ideas about where Siegall is going with his career. Right now he is busy with tapping many of the opportunities to market his treatment drugs and sell the proprietary products that Siegall has produced through Seattle Genetics. It is also the source of pride for Siegall that the ADCetris that he is developing could be the next breakthrough medicine today. It has recently been approved by the FDA, which is a relief considering the expensive costs of developing it. This is also an achievement that Siegall takes honor from mainly because it took 10 years before the product became profitable in the IPO level.
About Clay Siegall
A good executive profile describing the career of Clay Siegall would have to start by saying that he founded his Seattle Genetics firm in 1998. He is also the company’s President as well as its Chief Executive Officer. He also holds the responsibility for being the firm’s Chairman of the Board of Directors.
Through Siegall’s guidance, Seattle Genetics has raised a lot of capital-raising activities that made it possible for the company to secure a $675 million deal in public and private financings. Its initial public offering went live in 2001.